FDA Warning Letters vs. Untitled Letters: The Distinction That Sets Your Response Clock

Pull FDA's public warning-letter database and you will find violations that look identical to ones cited in the agency's untitled letters — a deficient CAPA, a mislabeled claim, a quality-system gap. The citation's language does not tell you which letter you are going to get. What decides it is a threshold FDA's Regulatory Procedures Manual sets, not the Federal Food, Drug, and Cosmetic Act: whether the violation's regulatory significance clears the bar for a formal warning. Below that bar, a company gets an Untitled Letter — no “WARNING” heading, no fixed response clock, and a dangerously common habit of being filed and forgotten.

What actually separates the two letters

FDA's compliance officers classify advisory correspondence using Chapter 4 of the Regulatory Procedures Manual (RPM), most recently revised in July 2024. A Warning Letter is reserved for violations FDA judges to have genuine regulatory significance — the kind that, left uncorrected, could support an enforcement action such as seizure, injunction, or prosecution. An Untitled Letter cites a violation FDA does not consider to have cleared that bar yet. Same inspection, sometimes the same CFR citation — a different agency judgment about what the facts add up to.

The clock only one of them starts

A standard Warning Letter's closing paragraph states the expectation directly: within fifteen working days of receipt, notify the issuing office in writing of the specific steps taken to correct the violations, including how the firm will prevent their recurrence. FDA guidance documents and the RPM do not themselves establish legally enforceable obligations — they describe the agency's current thinking and its own operating procedure — but an inadequate or late response is exactly the kind of signal that moves a case toward reinspection, a follow-up Warning Letter, or referral for formal enforcement. Firms that already run a inspection-readiness program typically have this response discipline built in for Warning Letters. Fewer have it built in for the letter that doesn't name a deadline.

• Warning Letter. Carries the “WARNING LETTER” heading, documents a violation FDA judges has regulatory significance, and states the fifteen-working-day response expectation in its own closing paragraph.
• Untitled Letter. No warning heading, no enforcement statement, and a response request pegged to a “reasonable” timeframe FDA does not define numerically.
• What doesn't change. Both letters expect a written response addressing root cause, not just the instance cited — and both sit in the same compliance-officer judgment chain that decides what happens next.
• What a weak response does. An inadequate reply to either letter — not just a missed deadline — is evidence FDA can cite when deciding whether the next step is reinspection, a Warning Letter, or formal enforcement.

An Untitled Letter is not FDA being lenient. It is FDA telling you the violation hasn't crossed the regulatory-significance line yet — and leaving the next inspection to decide whether it does. Why the response matters more than the deadline

Why the open-ended deadline is the trap

Companies with mature Warning Letter procedures often route Untitled Letters to a slower queue, precisely because no fixed day count forces escalation. The response gets drafted without the same root-cause rigor a Warning Letter triggers, especially when multiple business units are involved. That is backwards: FDA is evaluating the adequacy of the response, not just whether one arrived, and a thin reply becomes a second data point. If the same deficiency shows up again on the next inspection — whether that inspection runs under the device program's new QMSR inspection model or a standard drug GMP inspection — FDA now has a pattern, and a pattern is exactly what turns an Untitled Letter into a Warning Letter, or a Warning Letter into something that reaches a mock inspection wouldn't have caught in time.

None of this requires a legal department to manage. It requires a CAPA remediation process that treats “no fixed deadline” as a priority signal, not a reprieve. Companies that build one response discipline for both letter types are the ones whose Untitled Letters stay Untitled. If you're drafting a response after a prior one fell short — see how that gap compares to a 483 response, which starts its own clock even earlier — our inspection-readiness and CAPA teams build the root-cause narrative FDA is actually testing for.